Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer
出版年份 2022 全文链接
标题
Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer
作者
关键词
-
出版物
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-18
DOI
10.1007/s00432-022-04048-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies
- (2021) Matthew Lee et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2021) Beung-Chul Ahn et al. Cancers
- Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia
- (2020) Raffaele Frazzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Progress on treatment of MET signaling pathway in non-small cell lung cancer
- (2020) Xiaoqing Yu et al. International Journal of Clinical Oncology
- MET-dependent solid tumours — molecular diagnosis and targeted therapy
- (2020) Robin Guo et al. Nature Reviews Clinical Oncology
- Targeting MET Dysregulation in Cancer
- (2020) Gonzalo Recondo et al. Cancer Discovery
- Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis
- (2020) Tobias Raphael Overbeck et al. Translational Lung Cancer Research
- High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
- (2020) Shibo Wu et al. Annals of Translational Medicine
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anwendungen der FISH in der Diagnostik von Lungenkarzinomen
- (2020) Lena Hieggelke et al. PATHOLOGE
- Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
- (2020) Brendan P. Hodkinson et al. Translational Oncology
- Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib
- (2019) Xuanxuan Zheng et al. LUNG CANCER
- Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
- (2019) Gillianne G.Y. Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non–Small-Cell Lung Cancer
- (2019) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
- (2019) Ayesha Murtuza et al. CANCER RESEARCH
- Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)
- (2019) Fady M. Mikhail et al. GENETICS IN MEDICINE
- Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
- (2019) Re-I Chin et al. Molecular Diagnosis & Therapy
- Barcode sequencing identifies resistant mechanisms to EGFR ‐inhibitors in circulating tumor DNA of lung cancer patients
- (2019) Satoru Kitazono et al. CANCER SCIENCE
- Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial
- (2019) Lorenza Landi et al. CLINICAL CANCER RESEARCH
- How liquid biopsies can change clinical practice in oncology
- (2019) G Siravegna et al. ANNALS OF ONCOLOGY
- Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
- (2018) N Guibert et al. ANNALS OF ONCOLOGY
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Sun Min Lim et al. CANCER TREATMENT REVIEWS
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer
- (2018) Lianghua Fang et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
- (2018) Roberta Castiglione et al. MODERN PATHOLOGY
- Current and future perspectives of liquid biopsies in genomics-driven oncology
- (2018) Ellen Heitzer et al. NATURE REVIEWS GENETICS
- A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
- (2017) Eric Angevin et al. EUROPEAN JOURNAL OF CANCER
- OA 12.08 Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification
- (2017) S. Ou et al. Journal of Thoracic Oncology
- Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer
- (2017) Xiaowei Mao et al. Journal of Thoracic Oncology
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
- (2017) Alexander Drilon et al. Journal of Thoracic Oncology
- Current and Emerging Applications of Droplet Digital PCR in Oncology
- (2017) Susana Olmedillas-López et al. Molecular Diagnosis & Therapy
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis
- (2017) Nieves Perdigones et al. PHARMACOLOGY & THERAPEUTICS
- Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
- (2016) J. C. Thompson et al. CLINICAL CANCER RESEARCH
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
- (2016) J. H. Tong et al. CLINICAL CANCER RESEARCH
- Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
- (2016) Sinéad A. Noonan et al. Journal of Thoracic Oncology
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- Droplet digital PCR measurement of HER2 in patients with gastric cancer
- (2015) H Kinugasa et al. BRITISH JOURNAL OF CANCER
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
- (2014) H.-U. Schildhaus et al. CLINICAL CANCER RESEARCH
- Targeting MET Amplification as a New Oncogenic Driver
- (2014) Hisato Kawakami et al. Cancers
- Lung Cancer: Epidemiology, Etiology, and Prevention
- (2011) Charles S. Dela Cruz et al. CLINICS IN CHEST MEDICINE
- Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
- (2011) Aya Tanaka et al. LUNG CANCER
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started